News

Follow us on

KEW announces published paper in the Journal of Personalized Medicine. April 9, 2018
Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations. http://kewinc.com/wp-content/uploads/2018/04/Journal-of-Personalized-Medicine_Genomic-Profiling_Jan2018.pdf

KEW announces partnership with Invitae. March 16, 2018

Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information.  http://kewinc.com/wp-content/uploads/2018/03/Invitae_KEW-press-release_FNL_03152018.pdf

KEW announces Characterization of biomarkers to immune checkpoint blockade therapy across solid tumors at ASCO SITC. January 26, 2018.
Immune checkpoint blockade (ICB) therapy has been effective patients with solid tumors. Currently, tumor expression of programmed death-ligand 1 (PD-L1) is clinically used as a biomarker of predicted response to ICBs in non-small cell lung cancer (NSCLC). However, across solid tumors, only a subset of patients benefit from ICBs, so there is need to identify other biomarkers to predict response to ICB. We investigated the use of large panel next generation sequencing (NGS) to characterize biomarkers to ICBs across solid tumors. Read Article>  https://meetinglibrary.asco.org/record/156658/abstract

KEW announces Characterization of tumor mutation burden (TMB) and microsatellite instability (MSI) interplay for gastroesophageal adenocarcinoma (GA) and colorectal carcinoma (CRC) at ASCO SITC, January 26, 2018.

Tumor genomic instability is positively correlated with immunotherapy response. It confers different tumor phenotypes, including high TMB (TMB-H) and high MSI (MSI-H). Recently the US Food and Drug Administration approved MSI-H phenotype as a biomarker for immunotherapy, highlighting its importance, but also bringing up the question of how TMB as another promising biomarker is going to add value in the field. Here, we characterized TMB and MSI profiles to better understand the potential TMB contribution and identify genomic markers for it. Read Articlehttps://meetinglibrary.asco.org/record/156675/abstract

 

KEW Announces Publication of Analytical Validation Data 06/02/2017

The study demonstrates KEW’s orthogonal validation of somatic genomic variants in solid tumors characterized by CANCERPLEX® with specificity and sensitivity >99.5%. Overall clinical actionability was 93% in...Read Article >

Clinical application of a cancer genomic profiling assay to guide precision medicine decisions 

Read Article >

KEW, Inc. Appoints Jerry Williamson as President and CEO 

Read Article >

Notice of Establishment: New Company, Denka-KEW Genomics 

Read Article >

KEW, Inc. Receives 2016 Best of Cambridge Award 

Read Article >

KEW and the National Foundation for Cancer Research Announce Collaboration to Increase Awareness of CANCERPLEX® 

Read Article >

KEW Announces 2016 ASCO Abstract 

Read Article >

KEW Announces Name Change and Receives College of American Pathologists (CAP) Accreditation 

Read Article >

KEW’s CancerPlex® molecular diagnostic test made available for cancer patients in EU through myTomorrows platform 

Read Article >

 

KEW Group and Denka Collaborate on a Study to Identify the Benefits of CancerPlex® NGS Testing In Japanese Cancer Patients 10/20/2015

Read Article >

Tom Miller Joins KEW Group as Independent Director 

Read Article >

Genomic Expression and KEW Group to Collaborate 

Read Article >

KEW Group Raises $16.8 Million in Series B Financing 

Read Article >

KEW Group Inc. Announces Completion of Private Financing Round 

Read Article >

KEW Group Launches CancerPlex® Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists 

Read Article >  

Media & Investor Contact

media@kewinc.com

(855) 225-4068

Events

NGS Webinar

Size does matter. Provide the level of care you would want for your own loved ones.

Read More >

AACR Annual Meeting 2017 – Abstract: Genomic Profiling of the Tumors Harboring Activating EGFR Mutations

EGFR is a receptor tyrosine kinase of the HER/ERBB family and an oncogenic driver, especially for NSCLC, HNSCC and CRC.  EGFR targeted therapies have been successfully used for treating cancer patients harboring activating EGFR mutations.  However a main challenge is acquired drug resistance due to mutations or alternative signaling.  While developing next generation drugs is…

Read More >

Call us

855.225.4068

Email

kewcustomercare@kewinc.com

Location

840 Memorial Drive, 4th Floor Cambridge, MA 02139